Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8648604rdf:typepubmed:Citationlld:pubmed
pubmed-article:8648604lifeskim:mentionsumls-concept:C0026339lld:lifeskim
pubmed-article:8648604lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:8648604lifeskim:mentionsumls-concept:C0205145lld:lifeskim
pubmed-article:8648604lifeskim:mentionsumls-concept:C0005456lld:lifeskim
pubmed-article:8648604lifeskim:mentionsumls-concept:C0439855lld:lifeskim
pubmed-article:8648604lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:8648604lifeskim:mentionsumls-concept:C0887820lld:lifeskim
pubmed-article:8648604lifeskim:mentionsumls-concept:C0449445lld:lifeskim
pubmed-article:8648604lifeskim:mentionsumls-concept:C0121925lld:lifeskim
pubmed-article:8648604pubmed:issue8lld:pubmed
pubmed-article:8648604pubmed:dateCreated1996-7-25lld:pubmed
pubmed-article:8648604pubmed:abstractTextSeveral molecular modeling techniques were used to generate an all-atom molecular model of a receptor binding site starting only from Ca atom coordinates. The model consists of 48 noncontiguous residues of the non-nucleoside binding site of HIV-1 reverse transcriptase and was generated using a congeneric series of nevirapine analogs as structural probes. On the basis of the receptor-ligand atom contacts, the program HINT was used to develop a 3D quantitative structure activity relationship that predicted the rank order of binding affinities for the series of inhibitors. Electronic profiles of the ligands in their docked conformations were characterized using electrostatic potential maps and frontier orbital calculations. These results led to the development of a 3D stereoelectronic pharmacophore which was used to construct 3D queries for database searches. A search of the National Cancer Institute's open database identified a lead compound that exhibited moderate antiviral activity.lld:pubmed
pubmed-article:8648604pubmed:languageenglld:pubmed
pubmed-article:8648604pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648604pubmed:citationSubsetIMlld:pubmed
pubmed-article:8648604pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648604pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648604pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648604pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648604pubmed:statusMEDLINElld:pubmed
pubmed-article:8648604pubmed:monthAprlld:pubmed
pubmed-article:8648604pubmed:issn0022-2623lld:pubmed
pubmed-article:8648604pubmed:authorpubmed-author:EricksonJ WJWlld:pubmed
pubmed-article:8648604pubmed:authorpubmed-author:BALZFFlld:pubmed
pubmed-article:8648604pubmed:authorpubmed-author:PattabiramanN...lld:pubmed
pubmed-article:8648604pubmed:authorpubmed-author:ZaharevitzD...lld:pubmed
pubmed-article:8648604pubmed:authorpubmed-author:GussioRRlld:pubmed
pubmed-article:8648604pubmed:authorpubmed-author:KelloggG EGElld:pubmed
pubmed-article:8648604pubmed:authorpubmed-author:RiceW GWGlld:pubmed
pubmed-article:8648604pubmed:authorpubmed-author:SchaefferC...lld:pubmed
pubmed-article:8648604pubmed:authorpubmed-author:TopolI AIAlld:pubmed
pubmed-article:8648604pubmed:issnTypePrintlld:pubmed
pubmed-article:8648604pubmed:day12lld:pubmed
pubmed-article:8648604pubmed:volume39lld:pubmed
pubmed-article:8648604pubmed:ownerNLMlld:pubmed
pubmed-article:8648604pubmed:authorsCompleteYlld:pubmed
pubmed-article:8648604pubmed:pagination1645-50lld:pubmed
pubmed-article:8648604pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8648604pubmed:meshHeadingpubmed-meshheading:8648604-...lld:pubmed
pubmed-article:8648604pubmed:meshHeadingpubmed-meshheading:8648604-...lld:pubmed
pubmed-article:8648604pubmed:meshHeadingpubmed-meshheading:8648604-...lld:pubmed
pubmed-article:8648604pubmed:meshHeadingpubmed-meshheading:8648604-...lld:pubmed
pubmed-article:8648604pubmed:meshHeadingpubmed-meshheading:8648604-...lld:pubmed
pubmed-article:8648604pubmed:meshHeadingpubmed-meshheading:8648604-...lld:pubmed
pubmed-article:8648604pubmed:meshHeadingpubmed-meshheading:8648604-...lld:pubmed
pubmed-article:8648604pubmed:meshHeadingpubmed-meshheading:8648604-...lld:pubmed
pubmed-article:8648604pubmed:meshHeadingpubmed-meshheading:8648604-...lld:pubmed
pubmed-article:8648604pubmed:year1996lld:pubmed
pubmed-article:8648604pubmed:articleTitleAll-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach.lld:pubmed
pubmed-article:8648604pubmed:affiliationFrederick Biomedical Supercomputing Center, National Cancer Institute-FCRDC, Frederick, Maryland 21702, USA.lld:pubmed
pubmed-article:8648604pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:8648604lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8648604lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8648604lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8648604lld:pubmed